




RealRate

PHARMACEUTICAL 2025

Arcutis Biotherapeutics Inc
Rank 112 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arcutis Biotherapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcutis Biotherapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Arcutis Biotherapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 210%, being 4.5% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	335,820
Cost of Goods Sold	19,128
Intangible Assets	9,479
Liabilities, Current	81,013
Liabilities, Non-Current	110,335
Other Assets	2,549
Other Compr. Net Income	-11
Other Expenses	27,815
Other Liabilities	0
Other Net Income	16,173
Other Revenues	196,542
Property and Equipment	1,041
Research and Development	76,420
Selling, General and Administrative Expense	229,391

Output Variable	Value in 1000 USD
Assets	348,889
Liabilities	191,348
Expenses	352,754
Revenues	196,542
Stockholders Equity	157,541
Net Income	-140,039
Comprehensive Net Income	-140,044
BaseVar	552,858
ECR before LimitedLiability	75%
Economic Capital Ratio	210%